Not practical to shift generic drug manufacturing to US: Dr Reddy's CEO on Trump's tariff plan
Dr. Reddy's CEO has stated that shifting generic drug manufacturing to the United States is not a practical solution in response to proposed tariff plans. The executive highlights the logistical and economic challenges of relocating complex pharmaceutical supply chains.
Why it matters
This highlights the potential impact of protectionist trade policies on global pharmaceutical supply chains and drug affordability.
You are using an outdated browser. Please upgrade your browser to improve your experience and security.
Start --> Quotes Mutual Funds ETFs Commodities Futures & Options Unlisted Shares Currency News Topic Cryptocurrency Forum Notices Videos Glossary All My Alerts Go Ad-Free Hello, Login Hello, Login Log-in or Sign-Up My Account
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in